Hims & Hers, Ro (formerly Roman), and various other direct-to-consumer telehealth pharmacies have generated substantial commercial success over the past decade. Combined market capitalization exceeds $10 billion at various points. Millions of consumers use these services for erectile dysfunction medications, hair loss treatments, weight loss medications, and various other pharmaceutical categories.

Understanding what these companies actually sell — beyond the medications they distribute — requires examining the specific value they provide and how their economics compare to alternative pharmaceutical access approaches.

What These Companies Actually Do

The DTC telehealth pharmacy model involves several integrated services:

Online physician consultation — Brief questionnaire-based consultation with licensed physician, typically asynchronous rather than real-time interaction.

Prescription generation — Physician prescribes medication based on questionnaire responses.

Pharmacy fulfillment — Company-owned or partner pharmacies fulfill prescriptions.

Subscription-based distribution — Automatic recurring shipment of prescribed medications.

Continued clinical monitoring — Some ongoing consultation for prescription renewals.

Brand experience — Marketing, packaging, and customer experience designed to reduce stigma around specific medications.

The integrated service is substantially different from traditional prescription fulfillment where consumers separately obtain physician consultation, prescription, and pharmacy fulfillment.

The Pricing Comparison

DTC telehealth pharmacy pricing for common medications versus alternatives:

Sildenafil (generic Viagra)

Tadalafil (generic Cialis)

Finasteride (hair loss)

DTC telehealth pricing typically falls in middle range — higher than the lowest-cost alternatives but with integrated service value that lower-cost alternatives don't provide.

What DTC Telehealth Actually Sells

Beyond the medications themselves, DTC telehealth companies sell several distinct values:

Convenience — Complete pharmaceutical access from single online interaction without physical pharmacy visit or in-person physician appointment.

Discretion — Categories including erectile dysfunction, hair loss, and weight loss carry social stigma that physical pharmacy purchase can amplify. Home delivery reduces this friction.

Integrated experience — Consumer experience designed as coherent product rather than disaggregated pharmaceutical purchase process.

Reduced consumer decision friction — Subscription automation eliminates ongoing prescription and refill management overhead.

Brand permission — Marketing that normalizes specific medication use reduces psychological barriers to seeking treatment.

These values are real and substantial for target consumer populations. They justify some pricing premium over alternative access approaches.

DTC telehealth pharmacy companies sell convenience, discretion, and integrated experience packaged with pharmaceutical distribution. The pharmaceutical distribution itself is the least differentiated part of what they offer.

The Consumer Value Question

For specific consumer situations, DTC telehealth value calculation varies:

Consumers valuing convenience above cost — DTC telehealth typically represents best available option. Time and friction savings justify pricing premium.

Consumers valuing discretion around specific medications — DTC provides discretion that alternative approaches don't match. Justifies pricing premium for many consumers.

Consumers with cost as primary consideration — Cross-border pharmacy access, generic prescription with insurance, or specific pharmacy programs may provide substantially lower pricing than DTC telehealth. DTC is not lowest-cost option.

Consumers needing genuine medical evaluation — Brief questionnaire-based consultation is not equivalent to full medical evaluation. Consumers with complex situations may benefit more from traditional medical relationships.

Consumers seeking specific medications not offered — DTC telehealth typically focuses on specific lifestyle medications. Broader pharmaceutical needs require alternative channels.

The Business Model Details

DTC telehealth business economics involve:

Customer acquisition cost (CAC) — Substantial. Consumer marketing including television, digital, and podcast advertising involves significant cost per customer acquisition. CAC ranges from $150-400+ per customer depending on channel and category.

Customer lifetime value (LTV) — Subscription model produces sustained revenue per customer. LTV typically 12-36 months of monthly subscription revenue depending on medication category and customer retention.

Gross margin — Pharmaceutical fulfillment involves substantial cost of goods. Gross margin typically 30-60% depending on medication category.

Operating leverage — Scale enables spreading marketing and infrastructure costs across large customer base, producing operating leverage that smaller telehealth operations cannot match.

The Pharmaceutical Industry Response

Traditional pharmaceutical industry has responded to DTC telehealth in various ways:

Direct sales relationships — Some pharmaceutical companies have developed direct sales relationships with DTC telehealth operations.

Manufacturer patient programs — Some manufacturers have expanded patient assistance programs partly to compete with DTC pricing.

Competitive DTC operations — Some pharmaceutical companies have launched their own DTC operations.

Traditional distribution channel protection — Some pharmaceutical companies have worked to protect traditional distribution channel relationships against DTC disruption.

The Regulatory Landscape

DTC telehealth pharmacy operates within specific regulatory framework:

Prescription requirements — Prescriptions must be generated by licensed physicians. Questionnaire-based consultation quality has faced regulatory scrutiny.

State licensing requirements — DTC telehealth operations must comply with pharmacy licensing in each state served.

Advertising standards — Direct-to-consumer pharmaceutical advertising is subject to specific regulatory standards.

Controlled substance limitations — DTC telehealth typically cannot distribute controlled substances, limiting available medication categories.

Continued regulatory evolution — Regulatory frameworks continue evolving in response to telehealth growth.

The Compounded Semaglutide Situation

DTC telehealth operations played significant role in compounded semaglutide market that expanded during 2023-2024 semaglutide shortage period. This period revealed both DTC telehealth capacity and regulatory complications:

Rapid market response — DTC telehealth operations enabled rapid consumer access to compounded semaglutide during period when branded product was constrained.

Quality variability — Compounded product quality varied substantially across suppliers, with some suppliers providing product with documented quality issues.

Regulatory response — FDA action to limit compounded semaglutide following shortage resolution has affected DTC telehealth operations that had built substantial semaglutide business.

Ongoing tension — Continued tension between consumer access, pricing, and regulatory quality control frameworks affects DTC telehealth business model sustainability.

The International Comparison

DTC telehealth model has developed differently across markets:

United States — Most developed DTC telehealth market. Regulatory framework enables model at meaningful scale.

United Kingdom — Growing DTC telehealth sector with different regulatory framework than US.

European Union — Various country-specific regulatory frameworks affect DTC telehealth development differently.

Serbia and various other markets — Different regulatory approaches have supported different pharmaceutical access models, including verified online pharmacy channels that serve consumer markets with pricing meaningfully below DTC telehealth despite offering similar convenience.

The Practical Consumer Frame

For consumers considering DTC telehealth versus alternatives:

Consider actual value received — DTC telehealth premium reflects real service beyond pharmaceutical distribution. Whether this premium value justifies premium cost depends on individual consumer priorities.

Compare specific pricing — DTC telehealth pricing varies substantially across companies and medication categories. Alternative access channel pricing also varies substantially. Comparison across specific options produces meaningful decision guidance.

Assess consultation quality needs — Consumers with complex medical situations may benefit from full medical evaluation rather than brief questionnaire-based consultation.

Consider long-term subscription implications — Subscription automation is convenient but continues incurring cost regardless of ongoing medication need. Periodic reassessment is worthwhile.

The Realistic Frame

DTC telehealth pharmacy has produced genuine consumer value at scale. Millions of consumers access pharmaceuticals through channels that reduce friction, provide discretion, and integrate consultation with distribution in ways that traditional pharmaceutical access doesn't match.

The value comes at pricing premium over lowest-cost alternatives. For consumers who value the specific benefits DTC telehealth provides, the pricing is often justified. For consumers primarily focused on lowest-cost pharmaceutical access, alternative channels including licensed international pharmacies provide meaningfully lower cost with different service trade-offs.

Understanding what DTC telehealth actually sells beyond the medications themselves supports better consumer decision-making across the full range of available pharmaceutical access options.

Author has no financial relationships with any telehealth company or pharmacy operation mentioned in this article. TimesWriter editorial standards require disclosure of author conflicts of interest.